Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.

632 Incidence and prevalence of NMOSD in Australia and New Zealand W Bukhari, K M Prain, P Waters, M Woodhall, C M O’Gorman, L Clarke, R A Silvestrini, C S Bundell, D Abernethy, S Bhuta, S Blum, M Boggild, K Boundy, B J Brew, M Brown, W J Brownlee, H Butzkueven, W M Carroll, C Chen, A Coulthard, R C Dale, C Das, K Dear, M J Fabis-Pedrini, D Fulcher, D Gillis, S Hawke, R Heard, A P D Henderson, S Heshmat, S Hodgkinson, S Jimenez-Sanchez, T Killpatrick, J King, C Kneebone, A J Kornberg, J Lechner-Scott, M-W Lin, C Lynch, R Macdonell, D F Mason, P A McCombe, M P Pender, J A Pereira, J D Pollard, S W Reddel, C Shaw, J Spies, J Stankovich, I Sutton, S Vucic, M Walsh, R C Wong, E M Yiu, M H Barnett, A G Kermode, M P Marriott, J D E Parratt, M Slee, B V Taylor, E Willoughby, R J Wilson, A Vincent, S A Broadley Neuro-inflammation 639 Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response J-P Stellmann, M Krumbholz, T Friede, A Gahlen, N Borisow, K Fischer, K Hellwig, F Pache, K Ruprecht, J Havla, T Kümpfel, O Aktas, H-P Hartung, M Ringelstein, C Geis, C Kleinschnitz, A Berthele, B Hemmer, K Angstwurm, K L Young, S Schuster, M Stangel, F Lauda, H Tumani, C Mayer, L Zeltner, U Ziemann, R A Linker, M Schwab, M Marziniak, F T Bergh, U Hofstadt-van Oy, O Neuhaus, U Zettl, J Faiss, B Wildemann, F Paul, S Jarius, C Trebst, I Kleiter, on behalf of NEMOS (Neuromyelitis Optica Study Group)